- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 23 Dec 22 EFFECT Notice of effectiveness
- 21 Dec 22 POS AM Prospectus update (post-effective amendment)
- 28 Dec 21 424B3 Prospectus supplement
- 27 Dec 21 EFFECT Notice of effectiveness
- 17 Dec 21 POS AM Prospectus update (post-effective amendment)
- 14 Jan 21 424B4 Prospectus supplement with pricing info
- 12 Jan 21 EFFECT Notice of effectiveness
- 7 Jan 21 S-1/A IPO registration (amended)
-
6 Jan 21 S-1/A IPO registration (amended)
- 19 Nov 20 S-1 IPO registration
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference of our report dated October 14, 2020, relating to the consolidated statements of financial position of Lexaria Bioscience Corp. (the “Company”) as of August 31, 2020 and 2019, and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the years ended August 31, 2020 and 2019 of the Company and the reference to our name in the “Experts” section in the Company’s registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission on January 6, 2021.
“DAVIDSON & COMPANY LLP”
Vancouver, Canada | Chartered Professional Accountants |
|
|
January 6, 2021 |
|